Acute postoperative opioid consumption trajectories and long-term outcomes in pediatric patients after spine surgery

Mandy Mj Li1,2, Don Daniel Ocay2,3, Alisson R Teles2,4

  • 1Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

Insights

Postoperative opioid use in adolescents undergoing spinal fusion does not predict long-term outcomes. Intraoperative morphine dose influences acute opioid consumption, but long-term pain and function remain unaffected in pediatric patients.

Area of Science:

  • Pediatric Surgery
  • Pain Management
  • Adolescent Health

Background:

  • Opioid use post-surgery is linked to long-term outcomes in adults.
  • The association between acute postoperative opioid consumption and long-term outcomes in pediatric patients is not well understood.
  • Spinal fusion surgery in adolescents presents a critical period for opioid management.

Purpose of the Study:

  • To characterize opioid consumption patterns in the acute postoperative period following spinal fusion.
  • To identify predictors of these opioid consumption trajectories.
  • To determine if acute opioid use trajectories impact long-term patient outcomes.

Main Methods:

  • Adolescents undergoing spinal fusion had baseline assessments of pain, mental health, and medication use.
  • Cumulative opioid consumption was tracked for up to 5 days post-surgery.
  • Growth mixture modeling identified opioid consumption trajectories, with outcomes assessed at 6 months.

Main Results:

  • Five distinct opioid consumption trajectories were identified, categorizing patients into high and low consumers.
  • Intraoperative intrathecal morphine dose was a significant predictor of trajectory membership.
  • No significant association was found between acute postoperative opioid consumption and long-term pain, function, or medication use at 6 months.

Conclusions:

  • Intraoperative morphine dose influences acute postoperative opioid consumption in pediatric spine surgery patients.
  • Acute postoperative opioid consumption patterns do not appear to affect long-term outcomes in this pediatric population.
  • This suggests a potential disconnect between short-term opioid management and long-term recovery in adolescents.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
271
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
199
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
965
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
260
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.1K